These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 26250392)

  • 1. Deleterious BRCA1/2 mutations in an urban population of Black women.
    Lynce F; Smith KL; Stein J; DeMarco T; Wang Y; Wang H; Fries M; Peshkin BN; Isaacs C
    Breast Cancer Res Treat; 2015 Aug; 153(1):201-9. PubMed ID: 26250392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.
    Nanda R; Schumm LP; Cummings S; Fackenthal JD; Sveen L; Ademuyiwa F; Cobleigh M; Esserman L; Lindor NM; Neuhausen SL; Olopade OI
    JAMA; 2005 Oct; 294(15):1925-33. PubMed ID: 16234499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer.
    Armstrong K; Micco E; Carney A; Stopfer J; Putt M
    JAMA; 2005 Apr; 293(14):1729-36. PubMed ID: 15827311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer.
    Hall MJ; Reid JE; Burbidge LA; Pruss D; Deffenbaugh AM; Frye C; Wenstrup RJ; Ward BE; Scholl TA; Noll WW
    Cancer; 2009 May; 115(10):2222-33. PubMed ID: 19241424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent mutation testing of BRCA1 and BRCA2 in Asian breast cancer patients identify carriers in those with presumed low risk by family history.
    Kang PC; Phuah SY; Sivanandan K; Kang IN; Thirthagiri E; Liu JJ; Hassan N; Yoon SY; Thong MK; Hui M; Hartman M; Yip CH; Mohd Taib NA; Teo SH
    Breast Cancer Res Treat; 2014 Apr; 144(3):635-42. PubMed ID: 24578176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort.
    Greenup R; Buchanan A; Lorizio W; Rhoads K; Chan S; Leedom T; King R; McLennan J; Crawford B; Kelly Marcom P; Shelley Hwang E
    Ann Surg Oncol; 2013 Oct; 20(10):3254-8. PubMed ID: 23975317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer genetics in African Americans.
    Olopade OI; Fackenthal JD; Dunston G; Tainsky MA; Collins F; Whitfield-Broome C
    Cancer; 2003 Jan; 97(1 Suppl):236-45. PubMed ID: 12491487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.
    Sharma P; Klemp JR; Kimler BF; Mahnken JD; Geier LJ; Khan QJ; Elia M; Connor CS; McGinness MK; Mammen JM; Wagner JL; Ward C; Ranallo L; Knight CJ; Stecklein SR; Jensen RA; Fabian CJ; Godwin AK
    Breast Cancer Res Treat; 2014 Jun; 145(3):707-14. PubMed ID: 24807107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
    Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
    Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multi-gene panel study in hereditary breast and ovarian cancer in Colombia.
    Cock-Rada AM; Ossa CA; Garcia HI; Gomez LR
    Fam Cancer; 2018 Jan; 17(1):23-30. PubMed ID: 28528518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients.
    Eoh KJ; Park JS; Park HS; Lee ST; Han J; Lee JY; Kim SW; Kim S; Kim YT; Nam EJ
    Gynecol Oncol; 2017 Apr; 145(1):137-141. PubMed ID: 28159408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.
    Fostira F; Tsitlaidou M; Papadimitriou C; Pertesi M; Timotheadou E; Stavropoulou AV; Glentis S; Bournakis E; Bobos M; Pectasides D; Papakostas P; Pentheroudakis G; Gogas H; Skarlos P; Samantas E; Bafaloukos D; Kosmidis PA; Koutras A; Yannoukakos D; Konstantopoulou I; Fountzilas G
    Breast Cancer Res Treat; 2012 Jul; 134(1):353-62. PubMed ID: 22434525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of BRCA1 and BRCA2 gene mutations in Chinese patients with high-risk breast cancer.
    Wang X; Liu H; Maimaitiaili A; Zhao G; Li S; Lv Z; Wu D; Shi A; Guan X; Jia H; Li M; Song D; Kang L; Han B; Fu T; Yang M; Zhu Z; Du Y; Song Y; Hong J; Fan Z
    Mol Genet Genomic Med; 2019 Jun; 7(6):e677. PubMed ID: 30968603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA1 and BRCA2 mutations in a study of African American breast cancer patients.
    Pal T; Permuth-Wey J; Holtje T; Sutphen R
    Cancer Epidemiol Biomarkers Prev; 2004 Nov; 13(11 Pt 1):1794-9. PubMed ID: 15533909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.
    Capalbo C; Ricevuto E; Vestri A; Ristori E; Sidoni T; Buffone O; Adamo B; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
    Ann Oncol; 2006 Jun; 17 Suppl 7():vii34-40. PubMed ID: 16760289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of BRCA1 large genomic rearrangements to early-onset and familial breast/ovarian cancer in Pakistan.
    Rashid MU; Muhammad N; Amin A; Loya A; Hamann U
    Breast Cancer Res Treat; 2017 Jan; 161(2):191-201. PubMed ID: 27826754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between BRCA-associated breast cancer and age factors: an analysis of the Japanese HBOC consortium database.
    Okano M; Nomizu T; Tachibana K; Nagatsuka M; Matsuzaki M; Katagata N; Ohtake T; Yokoyama S; Arai M; Nakamura S
    J Hum Genet; 2021 Mar; 66(3):307-314. PubMed ID: 33046835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer.
    Hauke J; Horvath J; Groß E; Gehrig A; Honisch E; Hackmann K; Schmidt G; Arnold N; Faust U; Sutter C; Hentschel J; Wang-Gohrke S; Smogavec M; Weber BHF; Weber-Lassalle N; Weber-Lassalle K; Borde J; Ernst C; Altmüller J; Volk AE; Thiele H; Hübbel V; Nürnberg P; Keupp K; Versmold B; Pohl E; Kubisch C; Grill S; Paul V; Herold N; Lichey N; Rhiem K; Ditsch N; Ruckert C; Wappenschmidt B; Auber B; Rump A; Niederacher D; Haaf T; Ramser J; Dworniczak B; Engel C; Meindl A; Schmutzler RK; Hahnen E
    Cancer Med; 2018 Apr; 7(4):1349-1358. PubMed ID: 29522266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health Care Disparities in Hereditary Ovarian Cancer: Are We Reaching the Underserved Population?
    Randall TC; Armstrong K
    Curr Treat Options Oncol; 2016 Aug; 17(8):39. PubMed ID: 27315065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of Cancer Prevention: From Mammogram Screening to Identification of BRCA1/2 Mutation Carriers in Underserved Populations.
    Robinson LS; Hendrix A; Xie XJ; Yan J; Pirzadeh-Miller S; Pritzlaff M; Read P; Pass S; Euhus D; Ross TS
    EBioMedicine; 2015 Nov; 2(11):1827-33. PubMed ID: 26870808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.